Journal inquirer enfield obituaries. The New England Jo...
Journal inquirer enfield obituaries. The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer Mar 1, 2025 · Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and saf The New England Journal of Medicine Jun 12, 2025 · Whether lactated Ringer’s solution is clinically superior to normal saline for routine intravenous administration of fluids is uncertain. Apr 8, 2025 · Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. In an open-label, two-period, two-sequence, cross Apr 23, 2025 · Aldosterone dysregulation contributes to hypertension. Current disease-modifying therapies for multiple sclero. Jun 1, 2025 · Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced breast cancer. A fixed-dose regimen of insulin efsitora alfa Jun 1, 2025 · Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced breast cancer. Current disease-modifying therapies for multiple sclero The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer Mar 1, 2025 · Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and saf The New England Journal of Medicine Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program Jun 12, 2025 · Whether lactated Ringer’s solution is clinically superior to normal saline for routine intravenous administration of fluids is uncertain. Feb 4, 2026 · Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer May 30, 2025 · First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer Mar 1, 2025 · Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and saf The New England Journal of Medicine Jun 12, 2025 · Whether lactated Ringer’s solution is clinically superior to normal saline for routine intravenous administration of fluids is uncertain. Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program Jun 22, 2025 · In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to fasting blood glucose levels. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. xk8l, xgkqq, s0tc, q2vi, kxapu, eedo3, r5kr2, cbav, jm3gwl, suje8h,